Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of Cervarix in healthy females (HPV-013 Extension)
NCT00316706Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2005
- Primary completion
- Jan 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 3, open-label trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by GSK. Primary endpoint: Titers of Anti-human Papilloma Virus 16 and Anti-human Papilloma Virus 18 Antibodies at 48 months. Started Oct 2005; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT00316706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00316706.